Refractory neuromyelitis optica spectrum disorder in systemic lupus erythematosus successfully treated with rituximab

9Citations
Citations of this article
28Readers
Mendeley users who have this article in their library.
Get full text

Abstract

We present a case of a woman with systemic lupus erythematosus (SLE) who had refractory episodes of neuromyelitis optica spectrum disorder (NMOSD) and was successfully treated with rituximab. She was positive for anti-aquaporin-4 (AQP4) antibody and had typical cranial and longitudinally extended spinal lesions but no optic nerve involvement. There is no established treatment for NMOSD/SLE overlap cases. Our experience suggests that rituximab may be effective for patients with combined SLE and anti-AQP4 antibody-positive NMOSD.

Cite

CITATION STYLE

APA

Shidahara, K., Hayashi, K., Sada, K. E., Hiramatsu, S., Morishita, M., Watanabe, H., … Wada, J. (2018). Refractory neuromyelitis optica spectrum disorder in systemic lupus erythematosus successfully treated with rituximab. Lupus, 27(8), 1374–1377. https://doi.org/10.1177/0961203318760994

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free